TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Function Stop Before Hypoglycemia on External Insulin Pump

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* type I diabetic patients undr basal/prandial diet~* treated by insuline~* with no insuline pump during at least 3 months~* with HbA1C dosed during the 3 months before inclusion~Exclusion Criteria:~* minor patients~* pregnant woman~* already participating to another studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MiniMed™ 640G alone (Type: OTHER): MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
- MiniMed™ 640G + Captor CGM Enlite® (Type: OTHER): insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
- MiniMed™ 640G + Captor + SmartGuard® (Type: OTHER): insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, age ≥ 18 years~* Advanced or metastatic breast cancer, histologically confirmed~* Documented HER2 overexpression (IHC 3+ and/or FISH positive)~* At least one measurable lesion according to RECIST criteria. Patients with bone-only lesions are not eligible for study entry~* Documented disease progression~* Patients may have no more than 1 line of palliative treatment, however prior therapies must include trastuzumab in adjuvant or metastatic setting~* Life expectancy of at least 12 weeks~* Performance status 0-1~* Cardiac ejection fraction \>= 50% as measured by echocardiogram or MUGA scan~* Adequate hematology, liver and renal function~Exclusion Criteria:~* Pregnant or lactating women~* Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent~* Severe cardiac disease (uncontrolled angina, arrhythmia, chronic heart failure (CHF) or cardiac disease requiring a device)~* Ejection fraction below the institutional normal limit~* Maximum cumulative dose of 360 mg/m2 for doxorubicin and 720 mg/m2 for epirubicin~* Active bacterial, viral or fungal infection~* Patients with clinically apparent brain metastases~* Positivity for HIV, Hepatitis B or C~* History of other malignancy; patients who have been disease-free for 5 years~* Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy) or concurrent treatment with an investigational drug or participation in another clinical trial~* Known hypersensitivity to the study drugs Lapatinib and Caelyx or their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caelyx/Lapatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: FLOTRAC/VIGILEO in Acute Circulatory Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Systolic arterial pressure \< 90 mmHg or Mean arterial pressure \< 60 mmHg~* Heart rate \> 100 bpm~* Norepinephrine infusion~* Urine output \< 0.5 ml/kg/h during at least two consecutive hours~* skin mottling~* Capillary refill time \> 3 sec~Exclusion Criteria:~* Acute cor pulmonale~* Ongoing renal replacement therapy~* Lack of echogenicity during transthoracic echocardiography

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory Cells in Peritoneal Cavity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* woman over 18 year old undergoing exploration of ovarian cysts by coelioscopy~* patient with chronic renal insufficiency undergoing peritoneal dialysis~* informed consent obtained~Exclusion criteria:~* pregnancy or breast-feeding~* non affiliation to health care insurance~* treatment with corticosteroids over 15 mg/day~* treatment with rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- subjects with ovarian cyst (Type: OTHER): Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
- subjects with peritoneal dialysis (Type: OTHER): Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Revatio Portal-Pulmonary Arterial Hypertension Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with PPHTN.~* A 6MWD test between 150 m and 450 m.~* A pulmonary vascular resistance (PVR) \>250 dyn\*sec\*cm-5, a mean pulmonary artery pressure (PAPmean) ≥25 mmHg due to portal hypertension, and PCWP ≤ 15 mmHg. Right-heart catheterization results for the definite diagnosis of PH must follow the 2 - 6 week pre-treatment phase and not be older than 6 weeks at study start (will be considered as baseline values).~* Portal hypertension defined either clinically or hemodynamically by the presence of cirrhosis (by ultrasound or biopsy) or portal vein thrombosis / obstruction (proven by portal vein Doppler) and any one of the following within one year of entry into the study: 1) Ascites (on ultrasound of the abdomen); 2) Splenomegaly (on ultrasound of the abdomen); 3) Esophageal or Gastric Varices (proven endoscopically); 4) Hepatic-venous pressure gradient (HVPG) \> 12 mmHg.~* Treatment naive patients (with respect to PAH specific medication) and patients. Prior use of sildenafil for erectile dysfunction will be permitted.~* 18 to 75 years of age at Visit 1.~* Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period.~* Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures.~Exclusion Criteria:~* Participation in another clinical trial during the preceding 3 months.~* Pregnant women or breast feeding women.~* Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator or the sponsor.~* Patients with a history of severe allergies or multiple drug allergies.~* Patients with hypersensitivity to the investigational drug or inactive constituents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Revatio (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Hemiplegia Due to Stroke on the Microarchitecture of the Bone

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* at least 30 years~* vascular hemiplegia~* National Institute of Health Stroke Score equal 4 or greater with a motor of upper limb score greater than or equal 2 and a motor score of greater than or equal legs 2~Exclusion criteria~* Concomitant bone disease~* Endocrinopathies~* Phasic disorders understanding~* Contra-indication to MRI

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients (Type: None): Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 and older, with a physician diagnosis of asthma~* Current non-smoker with \< 10 pack-years smoking history and no smoking within the last year~* Stable asthma control over the last 3 months as defined by Asthma Control Test (ACT) ≥ 20 (40)~* Stable asthma medication regimen over the last 3 months~* FEV1 ≥ 70% predicted~Exclusion Criteria:~* Current smoking or ≥10 pack-years of smoking or any smoking within the last year~* Poor asthma control as defined by ACT\< 20~* Exacerbation of disease within previous 4 weeks~* Recent upper respiratory infection within last 4 weeks~* Acute or chronic rhinosinusitis~* Use of chronic nasal corticosteroids, or any use of nasal corticosteroids during the study~* Concomitant heart, lung or GI disease (liver, peptic ulcer) that would potentially jeopardize the safety of the participant or interfere with interpretation of the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tauroursodeoxycholic Acid (Type: EXPERIMENTAL): TUDCA 1750 mg daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed WHO grade IV supratentorial astrocytoma (glioblastoma multiforme)~  * Newly diagnosed disease~* Has undergone maximal surgical resection~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Serum creatinine \< 1.5 times upper limit of normal (ULN)~* AST or ALT \< 2 times ULN~* Serum bilirubin \< 1.5 mg/dL~* No known HIV infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior cranial radiotherapy~* More than 30 days since prior investigational agents~* No other concurrent investigational agents~* No concurrent use of any of the following drugs:~  * Antiarrhythmics (i.e., amiodarone or quinidine)~ * Antimycobacterials (i.e., rifampin)~ * Ergot derivatives (i.e., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)~ * Herbal products (i.e., St. John's wort)~ * HMG-CoA reductase inhibitors (i.e., lovastatin or simvastatin)~ * Neuroleptics (i.e., pimozide)~ * Sedatives and/or hypnotics (i.e., midazolam or triazolam)~* Concurrent corticosteroids allowed provided dose has been stable or decreasing for ≥ 14 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): NFV-RT-Tem

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient had a confirmed diagnosis of a select solid tumor (except ALK+ NSCLC) or hematological malignancy and was in need of treatment because of radiologic progression or relapse.~* Patient must have been pre-identified as having a tumor with an ALK or ROS1 positive mutation, translocation, rearrangement or amplification. The qualifying alteration must have been assessed and reported by a CLIA-certified laboratory. ALK positivity as assessed by IHC or FISH were allowed.~* Patient must have received at least one prior treatment for recurrent, metastatic and/or locally advanced disease and for whom no standard therapy options were anticipated to result in a durable remission.~* Patient had progressive and measurable disease as per RECIST 1.1 or other appropriate hematological guidelines.~* Patient had an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.~Exclusion Criteria:~* Patient had received prior treatment with ceritinib.~* Patients with symptomatic CNS metastases who were neurologically unstable or required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.~* Patient had received chemotherapy or anticancer therapy ≤ 4 weeks (6 weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceritinib 750 mg (Type: EXPERIMENTAL): Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of brain metastases from an extracranial primary site~  * Tumor ≤ 4 cm in maximal extent in any plane on contrast MRI~* Scheduled to undergo gross total resection of a single brain metastasis confirmed by histology~  * Up to 4 metastases allowed provided the largest mass is amenable to surgical resection and all non-resected masses are amenable to stereotactic radiosurgery (SRS)~* RTOG Recursive Partitioning Analysis (RPA) class 1 or 2, as defined by the following:~  * RPA class 1: Karnofsky performance status (KPS) 70-100%; age \< 65 years; controlled primary disease; and no extracranial metastatic disease~ * RPA class 2: KPS 70-100%; uncontrolled primary disease; and/or extracranial metastatic disease~* No lesion located in anatomic regions that are not amenable to SRS, including the brain stem, optic apparatus, or eloquent cortex~* No primary lesion with radiosensitive histology (e.g., small cell carcinoma, germ cell tumors, lymphoma, leukemia, or multiple myeloma)~* No radiographic or cytologic evidence of leptomeningeal disease~PATIENT CHARACTERISTICS:~* See Disease Characteristics~* Not pregnant or nursing~* Negative pregnancy test~* No concurrent uncontrolled illness including, but not limited to, any of the following:~  * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Psychiatric illness~* No contraindication to SRS, whole-brain radiotherapy, or MRI~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior brain surgery other than resection of metastasis~* No prior brain radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-Operative SRS (Type: EXPERIMENTAL): SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed MAIPC~* Documented progressive disease in bone, soft tissue or PSA despite castrate levels of testosterone~* If LHRH agonist were used previously it must be kept~* Previous anti-androgen should be held at least 4 weeks for flutamida or cyproterone and 6 weeks for bycalumida~* Previous DES should be held for at least 4 weeks before partcipating in the trial~* Chemotherapy naive patients~* No prior radioisotope~* Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy~* KPS\> 70%~* Adequate hematologic, hepatic and renal function~Exclusion Criteria:~* Patients with serious medical illness~* History of significant active cardiac disease~* History of gastrointestinal ulceration, bleeding or perforation~* History of myocardial infarctin within past 12 months~* Allergy to sulfonamides or to celecoxib or history of urticaria to any NSAID~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Medical Device Based on Polarized Light for Cutaneous Lesions Visualization

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient with a skin tumor (benign or cancerous) which has to be excised and analysed according to histopathological examination~* skin lesion belonging to one of these groups (diagnosed by clinical examination):~  * cutaneous cyst~ * seborrhoeic keratosis~ * cutaneous carcinoma~ * naevus~ * melanoma~ * actinic keratosis and cutaneous horn~ * other skin tumors~* skin lesion size equal to or less than 5 cm~* signed written consent form~* patient affiliated to a social insurance~Exclusion Criteria:~* skin lesion size strictly over than 5 cm~* eyelid lesion~* aluminium, POM (polyoxymethylene) or organic glass allergy~* known pregnancy, breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dermapol (Type: EXPERIMENTAL): Use of the experimental medical device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: New Technology for Individualised, Intensive Training of Gait After Stroke Study I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Patients aged 18-67 will be recruited from 1) the University Department of Rehabilitation Medicine at Danderyd Hospital in Stockholm and 2) Sahlgrenska University Hospital in Gothenburg, where they are admitted to inpatient rehabilitation early after stroke. Inclusion criteria will be: less than 8 weeks since stroke onset; inability to walk independently due to lower extremity paresis (i.e. Functional Ambulation Categories (FAC) score 0-1), able to sit on a bench with or-without supervision at least 5 minutes; sufficient postural control to allow upright position in standing with aids and/or manual support; ability to understand training instructions as well as written and oral study information and to express informed consent; body size compatible with the HAL suit. Exclusion criteria include: contracture restricting gait movements at any lower limb joint; cardiovascular or other somatic condition incompatible with intensive gait training; and severe, contagious infections.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 67 Years
- Healthy Volunteers: f

Study Arms:
- Hybrid Assistive Limb (HAL) (Type: EXPERIMENTAL): None
- Conventional gait training (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Pre-surgical Nasal Bacterial Reduction on Postoperative Surgical Site Infections / Standard Care Change

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting in the Emergency Department or admitted to the hospital with displaced hip fractures who require hemiarthroplasty or open reduction internal fixation or with spinal instability/fractures in need of urgent surgical intervention will be enrolled in the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single (Type: None): 3M Skin and Nasal Antiseptic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy